Compare Inovio Pharmaceuticals Inc (INO) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Wheaton Precious Metals Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Wheaton Precious Metals Corp trades at $136 (market cap $60.94B). The key difference: Wheaton Precious Metals Corp is far larger — about 775.8× Inovio Pharmaceuticals Inc's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | WPM | |
|---|---|---|
Market Cap | $78.55M | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $2.87 | $165.72 |
52-Week Low | $0.66 | $91.02 |
Enterprise Value | $49.56M | $62.82B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Wheaton Precious Metals (WPM) trades at $133.39, down 0.6% for the day, with a bullish technical signal driven by moving averages despite overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.19, supported by higher metal prices and sales volumes. Revenue surged to $2.31 billion in 2025, with net income reaching $1.47 billion, reflecting robust profitability margins.
The outlook remains positive with an 80% analyst buy rating and a $161.75 consensus price target, indicating ~21% upside. Key risks include reliance on commodity prices and projected negative cash flow in 2026. The stock's premium valuation (P/E 29.82) requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
